Table 3. Left Ventricular Dysfunction and Annualized Secondary Event Rates by Treatment Strategya.
| LV dysfunction | Total | Rivaroxaban | Aspirin | |||
|---|---|---|---|---|---|---|
| No. | Rate, %/y (No. of events) | No. | Rate, %/y (No. of events) | No. | Rate, %/y (No. of events) | |
| Normal to mildly impaired contractility without regional abnormality noted | 6605 | 5.8 (355) | 3323 | 6.2 (189) | 3282 | 5.4 (166) |
| Normal to mildly impaired contractility with regional abnormality noted | 405 | 5.6 (22) | 229 | 4.9 (12) | 273 | 9.5 (23) |
| Moderate to severely impaired contractility with or without regional abnormality noted | 97 | 13.3 (13) | ||||
a
The secondary outcome of this study was the main secondary efficacy outcome of the trial; that is, the composite of recurrent stroke, systemic embolism, myocardial infarction, or death from cardiovascular causes.